Skip to content
Open access

Hepatic adverse-event reporting after CAR T-cell therapy: a pharmacovigilance analysis of FAERS and Canada Vigilance

Oct 2026 · Annals of Hematology · 0 citations

TL;DR

Hepatic adverse events after chimeric antigen receptor (CAR) T-cell therapy may reflect cytokine release syndrome, immune effector cell-associated haemophagocytic syndrome/haemophagocytic syndrome/haemophagocytic lymphohistiocytosis, or immune-mediated drug-induced liver injury, which warrants prospective clinical evaluation.

Abstract

Hepatic adverse events after chimeric antigen receptor (CAR) T-cell therapy may reflect cytokine release syndrome (CRS), immune effector cell-associated haemophagocytic syndrome/haemophagocytic lymphohistiocytosis (IEC-HS/HLH), or immune-mediated drug-induced liver injury. We characterised product-specific hepatic adverse-event reporting and separated CRS-associated, HLH-associated, and residual patterns. We analysed deduplicated primary-suspect CAR T-cell reports in the FDA Adverse Event Reporting System (FAERS; 2016Q3-2026Q1), with directional comparison in Canada Vigilance. Hepatic events were identified using a prespecified 244-term MedDRA dictionary. The reporting odds ratio, proportional reporting ratio, information component, and empirical Bayes geometric mean were calculated for prespecified comparators. Sensitivity analyses excluded reports mentioning CRS or HLH and examined delayed-onset and hepatic phenotypes. Among 4,700,843 FAERS reports, 19,820 identified a CAR T-cell product as the primary suspect, and 734 contained hepatic events. Median onset was 5 days, with 73.5% occurring within 14 days. CRS was co-mentioned in 77.0% of hepatic reports, compared with 9.5% for HLH-spectrum terms. Excluding CRS reduced the pooled reporting odds ratio from 1.36 to 0.54, whereas excluding HLH preserved the association. Idecabtagene vicleucel showed the most consistent product-level pattern and retained a supportive pattern after excluding CRS-co-mentioned reports (ROR 2.22, 95% CI 1.38–3.57). No product retained four-method positivity beyond 14 days. Phenotype analyses identified product-specific mixed and cholestatic reporting patterns. Canada Vigilance showed a similar CRS co-mention proportion (75.0%), although the small number of hepatic adverse-event reports (n = 4) precluded meaningful product-level analysis. Hepatic adverse-event reporting after CAR T-cell therapy was predominantly early and possibly associated with CRS rather than HLH. Persistent CRS-independent reporting, particularly with idecabtagene vicleucel, warrants prospective clinical evaluation.

Read PDF

Similar papers

Open access Sep 2026

Safety Profile of Chimeric Antigen Receptor T-cell Therapies in Diffuse Large B-cell Lymphoma: An Analysis of Real-World Adverse Event Reporting From the FDA Adverse Event Reporting System

Objective To compare the real-world safety profiles of lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel) in patients with diffuse large B-cell lymphoma, leveraging data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database. Patients and Methods Case...

Magdi Elsallab, M. Lunning, Moataz Ellithi et al. · 0 citations
Open access Oct 2026

Infection-related adverse events associated with T-cell-engaging bispecific agents: A real-world pharmacovigilance study using FAERS/AEMS.

BackgroundT-cell-engaging bispecific agents and related T-cell-engaging therapies are increasingly used across hematologic malignancies and selected solid tumors. Infection is a clinically important safety concern, but infection-focused post-marketing comparisons across the current product set remain limited. We evalua...

Shui-Hua Liu, Ye Tan, Ai-Dong Chen et al. · 0 citations
Open access Oct 2026

Immune-effector and infection-associated reporting patterns of CD20×CD3 bispecific antibodies in B-cell lymphoma: a label-anchored FAERS analysis with descriptive JADER contextualization

Background CD20×CD3 bispecific antibodies are associated with acute immune-effector toxicities and infections, but drug-specific postmarketing co-reporting and report-level onset patterns remain incompletely characterized in B-cell lymphoma. Methods We performed a label-anchored FAERS pharmacovigilance analysis with de...

Hao Zhong, Yong-Jian Liu, Yan-Duan Lin et al. · 0 citations
Open access Nov 2026

Ocular adverse event profiles associated with endocrine therapies for breast cancer: a global pharmacovigilance study using FAERS and VigiAccess

Ocular adverse events may affect tolerability during long-term endocrine therapy for breast cancer, but comparative real-world evidence remains limited. We characterized ocular adverse-event reporting patterns using the FDA Adverse Event Reporting System (FAERS) and VigiAccess. FAERS reports from Q1–2004 to...

Xiao-Ping Wang, Wen-Zi Zuo, Cheng-Zhi Zhang et al. · 0 citations
Open access Sep 2026

Fluoropyrimidine-associated gastrointestinal toxicity: pharmacovigilance reporting signals and in vitro evidence of epithelial injury, barrier impairment, and inflammatory responses

Experimental evidence is provided that fluoropyrimidine exposure is associated with epithelial injury, impaired barrier function, and epithelial inflammatory responses, and the reporting signals do not estimate event frequency in treated populations or establish causality.

Xin-Chi Luan, Xiao-Ran Li, Xiao-Xuan Li et al. · 0 citations
Open access Oct 2026

Hepatobiliary adverse-event reporting patterns for endocrine therapies in breast cancer: a pharmacovigilance study based on FAERS and VigiAccess

Background Endocrine therapy is central to the treatment of hormone receptor-positive breast cancer, yet hepatobiliary adverse-event reporting across endocrine agents remains incompletely characterized. We evaluated hepatobiliary reporting patterns and disproportionality signals using FAERS, with VigiAccess as a supple...

Wei-Guo Mao, Yong-Hui Liu, Ben Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.